5 results about "Nuclear DNA" patented technology

The present invention relates to certain compounds that function as inhibitors of DHX9 activity (RNA Helicase A / RHA or Nuclear DNA Helicase II / NDH II). The present invention also relates to processes for the preparation of these compounds, to pharmaceutical compositions 5 comprising them, and to their use in the treatment of proliferative disorders, such as cancer, autoimmune and infectious diseases, as well as other diseases or conditions in which DHX9 activity is implicated.

This invention relates to a nuclear-targeted multimodal imaging diagnostic probe with BNCT therapeutic efficacy, its preparation, and its application, belonging to the fields of biomedicine and nuclear medicine technology. This boron drug contains... 10 Using acetylacetone difluoroborate as the parent nucleus, this invention endows the tumor with nuclear targeting ability by introducing N- or S-containing heterocyclic structures, while utilizing its conjugated structure to provide fluorescence / photoacoustic dual-modal imaging functionality. Based on this, the invention achieves three core functions: first, through fluorescence / photoacoustic dual-modal imaging, it enables the visual localization and real-time monitoring of tumor sites; second, by leveraging the binding of nuclear targeting groups to nuclear DNA / RNA, it... 10 B is precisely delivered into the nucleus, significantly improving the killing efficiency of BNCT; thirdly, thermal neutron irradiation is performed under imaging guidance, triggering... 10 The B(n,α)⁷Li nuclear fission reaction ultimately enables high-precision integrated diagnosis and treatment. This invention also discloses a method for preparing this probe, which has promising clinical application prospects.

This invention provides an Auger electron radiotherapy drug that can selectively and effectively release a sufficient amount of Auger electrons into the nuclear DNA of cancer cells, even in small amounts, thereby reducing or killing cancer cells. The Auger electron radioactive isotope has a half-life that is not too short but not too long, making it highly safe and readily available. [Solution] The Auger electron radioactive therapeutic agent is encapsulated in a stimulus-responsive liposome that accumulates in cancer tissue and / or cancer cells, such that an anthracycline derivative is released upon stimulation, in which an Auger electron-emitting radioisotope-substituted benzene ring-containing group or radioisotope-substituted alkyl group is covalently bonded to the keto or amino group of anthracyclines selected from doxorubicin or daunorubicin and their reduced forms or alkoxy group-substituted forms thereof, is a stimulus-responsive liposome, or is bound to an antibody, oligopeptide, or antigen that accumulates in cancer tissue and / or cancer cells via a stimulus-responsive linker.

Methods and materials for editing DNA (e.g., mitochondrial DNA) are provided herein. For example, chimeric polypeptides containing a nucleic acid interacting domain, a facilitating domain, and a base editing domain are provided herein, as are methods for using chimeric polypeptides to edit mitochondrial or nuclear DNA.

This invention discloses a method and system for detecting single-cell apoptosis using nuclear DNA-gated electrochemiluminescence microscopy. The method includes: culturing test cells on a transparent conductive substrate, with the substrate serving as the working electrode, placed in an electrochemical reaction cell; adding a detection solution to the electrochemical reaction cell; the detection system thus constructed utilizes genomic DNA within the cell nucleus as an endogenous biological co-reactant; applying an electrochemical excitation voltage to the working electrode in the detection system to induce an electrochemiluminescence reaction, while simultaneously capturing electrochemiluminescence images of the test cells using a microscopic imaging device; inputting the acquired electrochemiluminescence images into a pre-trained deep learning detection model; the model automatically identifies and outputs the apoptosis state category of each cell based on the electrochemiluminescence images, and statistically outputs the number of cells of each category and their proportion in the total number of cells.